BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Ismail A, Amer MS, Tawheed A. Glucagon-like peptide-1 receptor agonists: Evolution, gastrointestinal adverse effects, and future directions. World J Gastrointest Pharmacol Ther 2025; 16(3): 107148 [PMID: 40937289 DOI: 10.4292/wjgpt.v16.i3.107148]
URL: https://www.wjgnet.com/2150-5349/full/v16/i3/107148.htm
Number Citing Articles
1
Krishna Bonga, Milan Padhan. Incretin Analogues for Weight Reduction in Non-Diabetic Obese: A Review of Liraglutide, Semaglutide, and Tirzepatide Beyond Glycemic ControlRambam Maimonides Medical Journal 2026; 17(1): e0006 doi: 10.5041/RMMJ.10565
2
Nicole Ann Tesoro, Frederick Berro Rivera, Nathan Ross B. Bantayan, John Vincent Magalong, Romaine Tomada, Maria Antonia Wong, Gabriel Tangco, Polyn Luz Pine, Jasvin Kurundrayil Manha, Elora Shyama Tanni, Christine Lin, Sung-Ki Lee, Kyla Lara-Breitinger, Martha Gulati. Impact of Incretin Therapies on Biochemical and Imaging Outcomes in Metabolic Dysfunction–Associated Steatotic Liver DiseaseAmerican Journal of Preventive Cardiology 2026; : 101623 doi: 10.1016/j.ajpc.2026.101623
3
Riad Mohammed Abdelrahman, Taha Hussein Musa, Ismail Adam Arbab, Eltieb Omer Ahmed, Sahar Ibrahim Gasmallah, Mohammed Jalal, Chiamaka Linda Mgbechidinma, Wafaa Ramadan Ahmed. Adverse effects of GLP-1 receptor agonists: Clinical Implications, regulatory perspectives, and future directionsObesity Medicine 2026; 61: 100699 doi: 10.1016/j.obmed.2026.100699
4
Hanadi A. Hafth, Nawras A. Alwan, Eman Aboud Al-Masoudi. The effect of liraglutide on overweight and streptozotocin-induced diabetic male ratsINTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) 2026; 22(2): 159 doi: 10.22141/2224-0721.22.2.2026.1691